Company Info
Industry | Biotechnology |
---|---|
Sector | Health Technology |
Employees | 60 |
CEO | Mr. James E. Dentzer |
Address | 128 Spring Street Building C, Lexington, MA 02421 |
---|---|
Phone | 1.617.503.6500 |
Website | www.curis.com |
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
Statement Summary
as of 4:00 ET PM 05/20/2022Total Assets (MRQ) | 140.7 M |
---|---|
Total Liabilities (MRQ) | 64.8 M |
Shareholders’ Equity (MRQ) | 76.0 M |
Total Revenue (Annual) | 2.1 M |
Net Income (Annual) | -16.1 M |
Earnings And Estimates
as of 4:00 ET PM 05/20/2022
Current Qtr EPS Estimate | -0.17 |
---|---|
Current FY EPS Estimate | -0.68 |
Long Term EPS Growth Estimate | 0.00 |
Next Expected Earnings Date | 8/4/2022 |
CRIS vs S&P 500
as of 05/20/2022Relative To S&P 500 |
CRIS | |
---|---|---|
4 Weeks | n/a | n/a |
12 Weeks | n/a | n/a |
YTD | n/a | n/a |
Earnings Surprises
as of 4:00 ET PM 05/20/2022Fiscal Quarter | Estimate | Actual | Surprise |
---|---|---|---|
03/2022 | -0.16 | -0.18 | +12.50% |
12/2021 | -0.13 | -0.15 | +18.42% |
09/2021 | -0.13 | -0.12 | -7.69% |
06/2021 | -0.11 | -0.12 | +9.09% |
03/2021 | -0.09 | -0.11 | +19.57% |
12/2020 | -0.10 | -0.11 | +15.79% |
09/2020 | -0.13 | -0.11 | -15.38% |
06/2020 | -0.19 | -0.17 | -8.93% |
Financial Strength
as of 4:00 ET PM 05/20/2022Pre-Tax Margin | -783.13 |
---|---|
Net Margin | -72.69 |
Operating Margin | -735.68 |
Return On Equity | -52.17 |
Return On Assets | -31.16 |
Inventory Turnover (TTM) | 0.00 |
Sales Growth (MRQ) | 7.19 |
Ratios
as of 4:00 PM ET 05/20/2022Price/Earnings (TTM) | n/a |
---|---|
Price/Book (MRQ) | 0.96 |
Price/Cash Flow (TTM) | 0.00 |
Book Value (MRQ) | 0.83 |
Quick Ratio (MRQ) | 13.02 |
Current Ratio (MRQ) | 13.02 |
Total Debt/Equity (MRQ) | 0.74 |
Short Interest
as of 4:00 PM ET 05/23/2022% Short - 0.00% | |
% Remaining Float - 100.00% |
Current | Last Month | |
---|---|---|
Short Interest Date | n/a | n/a |
Short Interest Shares | 0 | 0 |
Short Interest Ratio | 0.0 | 0.0 |
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00
0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00
0,0.00
Cash from
Activities
0,0.00
0,0.00
Cash from
Fin. Activities
0,0.00
0,0.00
TOTAL ASSETS |
TOTAL LIABILITIES |
TOTAL EQUITY |
---|---|---|
Balance Sheet
M Y | ||||
---|---|---|---|---|
ASSETS | ||||
Cash And Equivalents | 0,0.00 | |||
Receivables | 0,0.00 | |||
Inventories | 0,0.00 | |||
Other Current Assets | 0,0.00 | |||
Total Current Assets | 0,0.00 | |||
Property, Plant & Equipment, Gross | 0,0.00 | |||
Accumulated Depreciation & Depletion | 0,0.00 | |||
Property, Plant & Equipment, Net | 0,0.00 | |||
Intangibles | 0,0.00 | |||
Other Non-Current Assets | 0,0.00 | |||
Total Non-Current Assets | 0,0.00 | |||
TOTAL ASSETS | 0,0.00 | |||
Liabilities & Shareholder Equity | ||||
Accounts Payable | 0,0.00 | |||
Short Term Debt | 0,0.00 | |||
Total Current Liabilities | 0,0.00 | |||
Long Term Debt | 0,0.00 | |||
Deferred Income Taxes | 0,0.00 | |||
Other Non-Current Liabilities | 0,0.00 | |||
Minority Interest | 0,0.00 | |||
Total Non-Current Liabilities | 0,0.00 | |||
Preferred Stock Equity | 0,0.00 | |||
Common Stock Equity | 0,0.00 | |||
Common Par | 0,0.00 | |||
Additional Paid In Capital | 0,0.00 | |||
Cumulative Translation Adjustment | 0,0.00 | |||
Retained Earnings | 0,0.00 | |||
Treasury Stock | 0,0.00 | |||
Other Equity Adjustments | 0,0.00 | |||
Total Capitalization | 0,0.00 | |||
TOTAL EQUITY | 0,0.00 | |||
TOTAL LIABILITIES & STOCK EQUITY | 0,0.00 | |||
Total Common Shares Outstanding | 0,0.00 | |||
Preferred Shares | 0,0.00 | |||
Treasury Shares | 0,0.00 | |||
Basic Weighted Shares Outstanding | 0,0.00 | |||
Diluted Weighted Shares Outstanding | 0,0.00 | |||
Number Of Employees | 0,0.00 | |||
Number Of Part-Time Employees | 0,0.00 |
TOTAL REVENUES |
EBT Excluding Unusual Items |
NET INCOME |
---|---|---|
Income Statement
M Y | |
---|---|
Sales | 0,0.00 |
Cost Of Sales | 0,0.00 |
Gross Operating Profit | 0,0.00 |
Selling, General, And Administrative Expenses | 0,0.00 |
Research & Development | 0,0.00 |
Operating Income Before D & A (EBITDA) | 0,0.00 |
Depreciation & Amortization | 0,0.00 |
Interest Income | 0,0.00 |
Other Income - Net | 0,0.00 |
Special Income / Charges | 0,0.00 |
Total Income Before Interest Expenses (EBIT) | 0,0.00 |
Interest Expense | 0,0.00 |
Pre-Tax Income | 0,0.00 |
Income Taxes | 0,0.00 |
Minority Interest | 0,0.00 |
Net Income From Continuing Operations | 0,0.00 |
Net Income From Discontinued Operations | 0,0.00 |
Net Income From Total Operations | 0,0.00 |
Extraordinary Income/Losses | 0,0.00 |
Income From Cum. Effect Of Acct. Change | 0,0.00 |
Income From Tax Loss Carryforward | 0,0.00 |
Other Gains / Losses | 0,0.00 |
Total Net Income | 0,0.00 |
Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0,0.00 |
Preferred Dividends | 0,0.00 |
Net Income Available To Common | 0,0.00 |
Basic EPS From Continuing Ops. | 0,0.00 |
Basic EPS From Discontinued Ops. | 0,0.00 |
Basic EPS From Total Operations | 0,0.00 |
Basic EPS From Extraordinary Inc. | 0,0.00 |
Basic EPS From Cum Effect Of Accounting Change | 0,0.00 |
Basic EPS From Tax Loss Carryf'd. | 0,0.00 |
Basic EPS From Other Gains (Losses) | 0,0.00 |
Basic EPS, Total | 0,0.00 |
Basic Normalized Net Income/Share | 0,0.00 |
EPS From Continuing Ops. | 0,0.00 |
EPS From Discontinued Ops | 0,0.00 |
EPS From Total Ops. | 0,0.00 |
EPS From Extraord. Inc. | 0,0.00 |
EPS From Cum Effect of Accounting Change | 0,0.00 |
EPS From Tax Loss Carfd. | 0,0.00 |
EPS From Other Gains (L) | 0,0.00 |
EPS, Total | 0,0.00 |
Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0,0.00 |
Dividends Paid Per Share | 0,0.00 |
CASH FROM OPERATIONS |
CASH FROM INVESTING ACTIVITIES |
CASH FROM FINANCING ACTIVITIES |
---|---|---|
Cash Flow Statement
M Y | ||||
---|---|---|---|---|
Cash Flow From Operating Activities | ||||
Net Income (Loss) | 0,0.00 | |||
Operating Gains/Losses | 0,0.00 | |||
Gross Operating Profit | 0,0.00 | |||
(Increase) Decrease In Receivables | 0,0.00 | |||
(Increase) Decrease In Inventories | 0,0.00 | |||
(Increase) Decrease In Other Current Assets | 0,0.00 | |||
(Decrease) Increase In Other Current Liabilities | 0,0.00 | |||
(Increase) Decrease In Other Working Capital | 0,0.00 | |||
Other Non-Cash Items | 0,0.00 | |||
Net Cash From Continuing Operations | 0,0.00 | |||
Net Cash From Discontinued Operations | 0,0.00 | |||
Cash Provided By Investing Activities | ||||
Net Cash From Total Operating Activities | 0,0.00 | |||
Sale Of Property, Plant & Equipment | 0,0.00 | |||
Cash Used For Investing Activities | ||||
Sale Of Short-Term Investments | 0,0.00 | |||
Purchases Of Property, Plant & Equipment | 0,0.00 | |||
Acquisitions | 0,0.00 | |||
Purchases Of Short-Term Investments | 0,0.00 | |||
Other Cash From Investing Activities | 0,0.00 | |||
Cash Provided by Financing Activities | ||||
Net Cash From Investing Activities | 0,0.00 | |||
Issuance Of Debt | 0,0.00 | |||
Cash Used For Financing Activities | ||||
Issuance Of Capital Stock | 0,0.00 | |||
Repayment Of Long-Term Debt | 0,0.00 | |||
Repurchase Of Capital Stock | 0,0.00 | |||
Payment Of Cash Dividends | 0,0.00 | |||
Other Financing Charges, Net | 0,0.00 | |||
Net Cash From Financing Activities | 0,0.00 | |||
Effect Of Exchange Rate Changes | 0,0.00 | |||
Net Change In Cash & Cash Equivalents | 0,0.00 |
Earnings Estimates
as of 4:00 ET PM 05/20/2022Current Qtr (06/2022) |
Next Qtr (09/2022) |
|
---|---|---|
Consensus Estimate | $-0.17 | $-0.17 |
# of Estimates | 6 | 6 |
High Estimate | $-0.16 | $-0.16 |
Low Estimate | $-0.17 | $-0.17 |
Year Ago EPS | $-0.12 | $-0.12 |
Year Over Year Growth Estimate | 40.77% | 38.20% |
Current Yr (12/2022) |
Next Yr (12/2023) |
|
---|---|---|
Consensus Estimate | $-0.68 | $-0.64 |
# of Estimates | 6 | 6 |
High Estimate | $-0.64 | $-0.22 |
Low Estimate | $-0.70 | $-0.84 |
Year Ago EPS | $-0.50 | $-0.68 |
Year Over Year Growth Estimate | 35.00% | -4.69% |
Current Qtr (06/2022) |
Next Qtr (09/2022) |
Current Year (12/2022) |
Next Year (12/2023) |
|
---|---|---|---|---|
Consensus Estimate | $-0.17 | $-0.17 | $-0.68 | $-0.64 |
# of Estimates | 6 | 6 | 6 | 6 |
High Estimate | $-0.16 | $-0.16 | $-0.64 | $-0.22 |
Low Estimate | $-0.17 | $-0.17 | $-0.70 | $-0.84 |
Year Ago EPS | $-0.12 | $-0.12 | $-0.50 | $-0.68 |
Year Over Year Growth Estimate | 40.77% | 38.20% | 35.00% | -4.69% |
Insider Information Summary
as of 04/30/2022% Insiders - 4.89% | |
% Remaining Total Shares - 95.11% |
Current | 1 Month | |
---|---|---|
Net Insider Transaction | -3.09 K | -5.50 K |
Shares Bought | 0.00 | 0.00 |
Shares Sold | 3.09 K | 5.50 K |
Insider Activity
Transaction Date | Insider/Title | Transaction Type | Market Value | Shares | Average Price | Current Holdings | ||||
---|---|---|---|---|---|---|---|---|---|---|
Latest News
Curis Drops; Lower Dose of Leukemia Drug to Reach Phase 2 Study
Jun 11, 2021 12:32 PM EDT
Curis Skyrockets on Positive Phase 1 Test for Lymphoma Treatment
Dec 8, 2020 10:19 AM EST
Biotech Premarket Movers: Spectrum, BioCryst, Curis
Mar 9, 2017 10:07 AM EST